Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points
Journal of Medicinal Chemistry · 25.01.2024 · 67 (2) · 1406-1420
DOI: 10.1021/acs.jmedchem.3c01967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.01.2024. Verfasst von Yusuke Oka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 7, Organic Anion Transporters. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Matrix metalloproteinase-7 (MMP-7) has been shown to play an important role in pathophysiological processes such as cancer and fibrosis. We previously discovered selective MMP-7 inhibitors by molecular hybridization and structure-based drug design. However, the systemic clearance (CLtot) of the biologically active lead compound was very high. Because our studies revealed that hepatic uptake by organic anion transporting polypeptide (OATP) was responsible for the high CLtot, we found a novel approach to reducing their uptake based on isoelectric point (IP) values as an indicator for substrate recognition by OATP1B1/1B3. Our "IP shift strategy" to adjust the IP values culminated in the discovery of TP0628103 (18), which is characterized by reduced in vitro OATP-mediated hepatic uptake and in vivo CLtot. Our in vitro-in vivo extrapolation of OATP-mediated clearance and the "IP shift strategy" provide crucial insights for a new medicinal chemistry approach to reducing the systemic clearance of OATP1B1/1B3 substrates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan.
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan.
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan.
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan.
ORCID-Profile: Yusuke Oka, Kumi Abe-Sato, Hideaki Tabuse, Tohru Yahara, Taiji Asami
Zitieren
APA
Oka, Y., Abe-Sato, K., Tabuse, H., Yasukawa, Y., Yahara, T., Nishimoto, T., Kamitani, M., Fukunaga, T., Ochiai, N., Kumasaka-Abe, T., Hitaka, K., Gunji, E., Ohara, H., Takeda, T., Kojima, N., & Asami, T. (2024). Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. Journal of Medicinal Chemistry, 67(2), 1406-1420. https://doi.org/10.1021/acs.jmedchem.3c01967
Vancouver
Oka Y, Abe-Sato K, Tabuse H, Yasukawa Y, Yahara T, Nishimoto T, et al. Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. Journal of Medicinal Chemistry. 2024;67(2):1406-1420. doi:10.1021/acs.jmedchem.3c01967
BibTeX
@article{Oka2024,
author = {Oka, Yusuke and Abe-Sato, Kumi and Tabuse, Hideaki and Yasukawa, Yoshifumi and Yahara, Tohru and Nishimoto, Tomohiro and Kamitani, Masafumi and Fukunaga, Takuya and Ochiai, Nagahiro and Kumasaka-Abe, Tomoko and Hitaka, Kosuke and Gunji, Emi and Ohara, Hiroki and Takeda, Takuya and Kojima, Naoki and Asami, Taiji},
title = {Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {2},
pages = {1406--1420},
doi = {10.1021/acs.jmedchem.3c01967}
}
EUVIMED